



Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis

Francis Fatoye¹ · Tadesse Gebrye¹ · Chidozie Mbada¹

Received: 13 July 2022 / Accepted: 5 August 2022 / Published online: 25 August 2022
© Crown 2022

Abstract

Systemic lupus erythematosus (SLE) may be more prevalent among most ethnic groups in the low-and-middle income countries (LMICs), still these countries are under-represented in epidemiological data on SLE. The aim of this study was to review the prevalence and incidence of SLE in LMICs and use meta-analytic techniques. The MEDLINE, CINAHL, Web of Science, Scopus and Global Index Medicus databases were searched for relevant studies published up to July of 2022. Papers selected for full-text review were included in the systematic review if they provided the prevalence or incidence of SLE in LMICs and published in English language. The reference lists of included articles were also searched for additional studies. Two individuals independently performed abstract and full-text review, data extraction, and quality assessment of the papers. The prevalence and incidence of SLE were pooled through random effects model. Pooled estimates were expressed with 95% confidence. Out of 2340 papers, 23 studies were included in the review. The mean age at diagnosis ranged from 25.5 to 45.8 years. Three studies were conducted in Argentina and Brazil, two studies in China and one study in Cuba, Colombia, Democratic Republic Congo, Ecuador, Egypt, India, Kenya, Malaysia, Mexico, Nigeria, Pakistan, Turkey, Ukraine, Venezuela, and Zimbabwe. The SLE prevalence and incidence varied from 3.2 to 159 per 100,000 and 0.3–8.7 per 100,000 persons, respectively. In a random effects meta-analysis ($n = 10$), the pooled prevalence of SLE was 103 (95% confidence interval [CI] – 17 to 224) per 100,000. Meta-analysis of data from 6 incidence studies revealed an incidence of 5 cases per year (95% CI 2–8) per 100,000. According to WHO regions, the pooled prevalence of American and Western Pacific regions was 300 (95% CI – 200 to 900) and 36 (95% CI 35–37) per 100,000, respectively. The pooled incidence of the American region was 10 (95%, 0–14) per 100,000 inhabitants. Systemic lupus erythematosus is a common disease with considerable variation in prevalence and incidence among the general population in LMICs. Accurate estimates of prevalence and incidence of SLE are required to put in place appropriate programmes to reduce its burden in LMICs. **PROSPERO registration number:** CRD: 42020197495, <https://www.crd.york.ac.uk/prospero/>.

Keywords Systemic lupus erythematosus · Systematic review · Incidence · Prevalence · LMICs

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that causes inflammation of connective tissues [1]. In general, SLE has propensity to affect every organ and tissue of the body, and its pattern of clinical manifestations

varies widely among patients [2]. The complex interactions among genetic disposition, environmental risk factors, and the hormonal status contribute to the clinical heterogeneity in clinical manifestation of SLE, thus making its often problematic or keenly dependent on clinical expertise, in addition to immunological findings [2–5].

The incidence and prevalence of SLE vary widely in population demographics, socioeconomic factors, and certain ethnic population, such as Hispanic population, black and Asian [1, 6–8]. Specifically, in Europe and North America, people of African descent [9, 10], American Indians and Alaska Natives [11, 12] have higher predilection and worse outcomes from SLE than Caucasians within the same

✉ Francis Fatoye
f.fatoye@mmu.ac.uk

¹ Department of Health Professions, Manchester Metropolitan University, Birley Fields Campus, Brooks Building, 53 Bonsall Street, Manchester M15 6GX, UK

contexts [13]. Therefore, there are numerous indications that SLE is less severe in patients of European ancestry than Asian, African, and certain “Hispanic” or various indigenous populations [6, 14]. In Australia, Canada and USA, SLE disease among aboriginal/indigenous individuals are twofold to fourfold more common compared to non-aboriginal individuals [15]. Furthermore, patients from Asia and African ancestry are also likely to have a greater number of clinical manifestations, active SLE onset and higher mortality than white populations [16].

The clinical technicalities and complexity with diagnosing SLE may have contributed to assertions that the disease is infrequent in Africa [9, 10]. However, emerging reports indicates that the prevalence of SLE in sub-Saharan African was 1.7% (0.8–2.9 which is lower than the Asian–Pacific countries [19]. The overall incidence and prevalence of SLE across Asian–Pacific countries ranged from 0.9 to 3.1 and 4.3–45.3 per 100,000, respectively [18]. Furthermore, the incidence of SLE in North America and Europe ranged from 3.7 to 49 and 1.5 and 7.4 per 100,000 person-years, respectively [20–22]. Evidence also suggests that there is a gradual increase of SLE prevalence in North America, Europe and Asia [17]. Though, study design reporting bias, case definitions and SLE classification criteria may also result to a variation of the proportion of the population that has SLE [17].

Despite the variation of SLE across all age groups, it is more common between the ages of 15 and 45 years [23]. Evidence showed that in 10–20% of patients with SLE disease starts in childhood, this is due to increased renal, neuropsychiatric and cardiopulmonary disease [24–26]. The gender disparity of SLE is also widely recognised with a 1: 9 ratio of male to female patients. The incidence and prevalence of SLE in females is usually highest at 15–44 and 45–64 years of age, respectively [11].

Due to environmental, genetic, and racial factors the prevalence and incidence of SLE varies across the various regions of the world. For instance, changes in environmental factors are associated with increased in SLE [27]. Furthermore, the severity and course of SLE may often be related to the difference education, health insurance status, income level, ethnicity, medication compliance and level of social support. The survival rate of SLE patients in LMICs is lower than high income countries, this is due to higher mortality, poor intervention, and co-morbidities of infection [28]. To date there is no systematic review that summarized the prevalence and incidence of SLE published in LMICs [11, 21, 29]. The aim of this review was to summarise the global and regional prevalence and incidence of SLE in LMICs.

Methods

This systematic review followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline [30]. The review was registered with PROSPERO—the International Prospective Register of Systematic Reviews CRD: 42020197495.

Data sources and search strategy

An electronic database search was carried out on titles and abstracts till 11th of July 2022. MEDLINE, CINAL, Web of Science, Scopus and Global Index Medicus databases and were used to search the literature. Search terms used were: lupus, systemic lupus erythematosus, disseminated lupus erythematosus, lupus erythematosus disseminates and libman-sacks disease, prevalence, incidence, epidemiology, and rheumatic disease (see Appendix for detailed search strategy). In addition to these databases, hand searches from the references of the included studies were also used. All references were downloaded to EndNote X8 and duplicates were removed.

Study selection

One reviewer (TG) conducted the search. Two independent researchers (TG & FF) screened titles and abstracts. The potential eligible papers were retrieved, and two reviewers (TG & FF) agreed the initial inclusion criteria. The inclusion criteria were population of all age groups with lupus, both retrospective and prospective study designs and prevalence and incidence estimates of lupus in LMICs and studies should be available in English and full text. LMIC classification was confirmed by cross-referencing with the World Bank list of Countries by Income Level. Conference proceedings, review articles, articles in press, abstracts or editorials were the exclusion criteria. Articles on SLE cases in the context of overlap syndrome were also excluded from the review. The classification for SLE was based on the 1982 American College of Rheumatology and/or revised 1997 American College of Rheumatology criteria [11, 31]. Any disagreement in study selection was resolved through discussion and consultation with a third reviewer (CM) where necessary.

Data extraction

Data were extracted from the full text articles by one (TG) of the authors using a predefined form. The data extracted included authors and date of the study, population and setting, ethnicity/race, case definition, incidence rate and prevalence. The extracted data were cross-checked by another

reviewer (FF). If disagreement occurred, consensus was reached through discussion.

Appraisal of individual study quality

Two independent reviewers (TG & FF) appraised the quality of the included studies. The included studies were assessed using a risk of bias tool developed by Hoy et al. [32]. The assessment tool consists of 10 items addressing the external and internal validity. This tool consists of ten items, including six items addressing internal validity (i.e., measurement reliability) and four items addressing external validity (i.e., representativeness of sample). The questions can be responded as ‘yes’ or ‘no’. The overall risk of bias for each study was evaluated low, moderate, and low. Studies with scores of 9 or 10 ‘yes’-answers were considered to have low risk of bias; studies with scores of 7 or 8 were considered to have moderate risk of bias and studies with scores of 6 or less were considered to have high risk of bias. Any disagreement was resolved by discussion with the third author (CM).

Data synthesis and analysis

Studies were included in the meta-analysis if they reported the number of SLE cases and sample denominator, the estimate with 95% CI, or the information with which to calculate the estimated prevalence or incidence. All studies reporting period prevalence were converted to annual prevalence estimate. A statistical heterogeneity was assessed with

I^2 , a statistic that estimates the percentage of total variation due to heterogeneity across studies, where 0–25% was low, 26–74% moderate and 75% and over high statistical heterogeneity [33]. All the pooled estimates and 95% confidence intervals were calculated using a random-effects model. The Comprehensive Meta-Analysis software version 3 (CMA.V3) (Biostat, Inc., Englewood, NJ, USA) were used to analyse the data [34, 35].

Results

Study selection and characteristics

The systematic literature search results are presented in Fig. 1. Out of 2,340 titles, 23 studies that summarise the prevalence and incidence of SLE in LMICs were included in the review. Of the 23 included papers, 16 had low risk of bias and the remaining 7 had moderate risk of bias. The full risk-of-bias assessment is shown in Table 1.

The characteristics of the included studies are presented in Table 1. The included studies were from European regions ($n=2$), Western Pacific regions ($n=3$), the American region ($n=11$), Eastern Mediterranean region ($n=2$), the African region ($n=4$) and Southeast Asia region ($n=1$). The included studies were carried out in 17 countries. The studies were contributed from Argentina ($n=3$), Brazil ($n=3$), China ($n=2$), Colombia, Ecuador, Egypt, Turkey, India, Malaysia, Pakistan, Ukraine, Venezuela, Zimbabwe,

Fig. 1 Flow diagram of publications included and excluded in the review




Table 1 Basic characteristics of the studies retained for the analyses

Study, country	Study population (Mean age, years)	WHO regions	Sample size	Ethnicity/Race (%)	Case definition	Prevalence/100,000	Incidence/100,000	Risk of bias
Gonzalez et al. 2016 [36]; Argentina	Tucuman population; (30.5 ± 11.7)	AMRO	904,188 W = 93.5% M = 6.5%	83 Mestizos and 17 were African-Latin American	ACR	24.3 (95% CI 22.6–28.8)	1.8 (95% CI 1–2.9) 4.2 (95% CI 2.9–5.8)	Low
Pamuk et al. 2016 [37]; Turkey	Rural and urban population in Turkey; (38.5)	EURO	620,477 W = 306,036 M = 314,411	N/A	ICD-10 code	51.7 (95% CI 46–57.4)	4.44	Low
Fernández-Ávila et al. 2019 [38]; Colombia	Colombian population (Over 18)	AMRO	47,663,162 W = 89% M = 11%	N/A	Not explicitly addressed	126.3	N/A	Low
Zou et al. 2014 [39]; China	General residents in rural Anhui, China (All age groups)	WPRO	1,358,725 M = 51.2%	All Chinese	ACR	36.03 (95% CI 35.54, 36.51)	N/A	Low
Ekwoom 2013 [40]; Kenya	Patients attended at Kenyatta National Hospital (34)	AFRO	394 W = 100%	Black Africans	ACR	3000 [95% 1800–5600]	N/A	Moderate
Gbané-Koné et al. 2015 [41]; Nigeria	Patients attended in rheumatology department's; (35.76)	AFRO	18,076	Black Africans	ACR	640 [95% 500–800]	N/A	Moderate
Wang et al. 1997 [42]; Malaysia	Patients attended in hospital (25.5 ± 10.1)	WPRO	539 W = 93%; Men = 7%	Chinese = 76 Malays = 17 Indians = 7	ACR	43	N/A	Moderate
Farooqi and Gibson 1998 [43]; Pakistan	Population in Punjab, Pakistan	EMRO	700	N/A	WHO-ILAR COPCORD study	50	N/A	Low
Taylor and Stein 1986 [44]; Zimbabwe	Patients attended Mpilo Hospital (28)	AFRO	31 W = 30; M = 1	Mestizos = 83	ACR revised criteria	N/A	0.3	Moderate
Nakashima et al. 2011 [45]; Brazil	Patients in Cas-cavel, state Paraná (41.5 ± 14.44)	AMRO	291,747 W = 149,790 M = 141,957	N/A	ACR	N/A	4.8	Low
Vilar et al. [46]; Brazil	Patients living in Natal (31.8)	AMRO	493,239 (W = 269,900; M = 223,339)	White = 77 Non-White = 23	ACR	N/A	8.7 (95% CI 6.3 – 11.7) W = 14.1 (95% CI 10.0 – 19.3) M = 2.2 (95% CI 0.7 – 5.2)	Low
Scolnik et al. 2014 [47]; Argentina	Patients attended in hospital, Buenos Aires	AMRO	127,959	All Caucasian	ACR	58.6 (95% CI 46.1–73.5)	6.3 (95% CI 4.9–7.7)	Low
Nasonov et al. 2014 [48]; Ukraine	Population in Ukraine (37)	EURO	367,500 M = 163,538 W = 203,962	98.6 Caucasian; 1.14 Asian	ACR	14.9 (95% CI 10.9–19.9)	0.3 (95% CI 0.0–1.8)	Low

Table 1 (continued)

Study, country	Study population (Mean age, years)	WHO regions	Sample size	Ethnicity/Race (%)	Case definition	Prevalence/100,000	Incidence/100,000	Risk of bias
Senna et al. 2004 [49]; Brazil	Individuals from Montes Claros (37)	AMRO	3038	White = 38 Non-White = 62	ACR	98	N/A	Moderate
Granados et al. 2015 [50]; Venezuela	Urban community in Venezuela (43.7)	AMRO	3,973 M = 1,606 W = 2,367	All Las Cocuizas	ACR	70 (95% CI 10–200)	N/A	Moderate
Pelaez-Ballestas et al. 2011 [51]; Mexico	Patients from México (42.8 (SD 17.9))	AMRO	4059	N/A	ACR	90 (95% 20–200)	N/A	Low
Li et al. 2012 [52]; China	Chinese population, (45.8)	WPRO	14,642	N/A	ACR	30 (95% CI 0–60)	N/A	Low
Malaviya et al. 1993 [53]; India	Northern Indian population	SEARO	91 888	N/A	ANA	3.2 (95% CI 0–6.86)	N/A	Low
Malemba and Mbuyi-Muamba 2008 [54]; DRC	Patients attending hospital (49.7 ± 13.1)	AFRO	2370 W = 55.3% M = 44.7%	Black Africans	ACR	100 [95% 60–1500]	N/A	Moderate
Reyes-Llerena et al. 2009 [56]; Cuba	Patients with musculoskeletal complaints	AMRO	3155 M = 1238; W = 1917	N/A	ACR	60 (95% CI 10–250)	N/A	Low
Gheita et al. 2021 [57]; Egypt	Patients of SLE across the nation (32.4 (SD 10.1))	EMRO	3661 (W = 3296; M = 365)	N/A	N/A	6.1	N/A	Low
Guevara-Pacheco et al. 2016 [55]; Ecuador	Patients living Cuenca City, 42.8 (SD 18.8)	AMRO	4877 (W = 59.7%)	N/A	COPCORD questionnaire	60 (95% CI 10–100)	N/A	Low
Quintana et al. 2016 [58]; Argentina	Patients in Rosario City (35.3 (SD 13.9))	AMRO	1656 (W = 61.5%)	N/A	WHO ICD-10	60 (95% CI 1–300)	N/A	Low

WPRO Western Pacific, AMRO American region, EMRO Eastern Mediterranean region, AFRO African region, ACR American College of Rheumatology criteria, N/A Not available, W Women, M Men, WHO-ILAR COPCORD World Health Organization and the International League of Associations for Rheumatology The Community Oriented Program for Control of Rheumatic Diseases, EURO European, ACR American College of Rheumatology criteria, ANA Anti-Nuclear Antibody test, DRC Democratic Republic of the Congo, COPCORD Community-Oriented Program for the Control of Rheumatic Diseases

Mexico, Democratic Republic Congo, Cuba and Nigeria and Kenya. The mean age at diagnosis ranged from 25.5 to 49.7 years.

Prevalence and incidence

The prevalence and incidence rates of SLE varied from 3.2 to 3000 per 100,000 and 1.4–8.7 per 100,000 persons, respectively. The highest and lowest prevalence rate of SLE were reported in Colombia and Ukraine, respectively. In relation to the incidence rate the highest and lowest rate was recorded in Brazil and Ukraine. In the random effects meta-analysis ($n = 10$), the pooled prevalence of SLE was 103 (95% CI – 17 to 223) per 100,000 (Fig. 2). Meta-analysis of data from five incidence studies revealed an incidence of 5 cases per year (95% CI: 2–8) per 100,000 (Fig. 3). According to WHO regions, the pooled prevalence of American region, Western Pacific regions and African region was 300 (95% CI – 200 to 900); 36 (95% CI 35–37) and 60 (95% CI – 40 to 1300) per 100,000, respectively. The pooled incidence of the American region was 10 (95% CI 0–14) per 100,000 persons.

Sex related prevalence and incidence

Out of the total, twelve of the included studies reported the sex related prevalence or incidence of SLE (Table 2). The prevalence and incidence of men ranged from 0 to 90

and 0.5 to 2.6 per 100, 000 inhabitants, respectively. For the female population, the prevalence and incidence of SLE ranged from 23.8 to 204.3 and 4.72 to 14.1 per 100, 000 persons, respectively. Overall, the prevalence and incidence of SLE among women are higher than men.

Three studies were identified that examined the prevalence and incidence of people with SLE over time, allowing us to examine its temporal trend in Argentina [47], Turkey [37] and Colombia [38] (Fig. 4). The incidence of SLE in Argentina showed a substantial increase over the period of 8 years, the annual incidence in 2005 was 1.8 cases/100.000 inhabitants (95% CI 1–2.9) and in 2012 of 4.2 cases/100.000 inhabitants (95% CI 2.9–5.8). In Turkey [37], the annual incidence between the period of 2003–2006 (4.75 per 100,000 persons) were higher than 2011–2014 (4.39 cases per 100,000 persons). Number of patients with SLE also showed increment in Colombia from 15,556 to 16,437 per 100,000 persons for 2012 and 2016, respectively.

Discussion

To our knowledge, this is the first review to evaluate and synthesise the incidence and prevalence data for SLE across the WHO regions of LMICs. This review represents a published data of prevalence and incidence of SLE from Argentina, China, Cuba, Colombia, Democratic Republic Congo,

Fig. 2 Prevalence of SLE across LMICs settings




Fig. 3 Incidence of SLE across LMICs settings. **a** Annual incidence of SLE, 2005–2012 in Tucuman, Argentina. **b** Incidence rates of SLE by 4-year periods (2003–2006, 2007–2010, 2011–2014) in Turkey. **c** Prevalence of SLE between 2012 and 2016 in Colombia




Table 2 Sex-related prevalence and incidence of SLE per 100,000

Study	Number (prevalence)		Number (incidence)	
	Men	Women	Men	Women
Pamuk et al. 2016 [36]	314,411 (7 (95% CI 4.1–9.9))	306,036 (97.7 (95% CI 86.6–108.8))	314,411 (0.64 (95% CI 0–1.52))	306,036 (8.4 (95% CI 5.2–11.6))
Fernández-Ávila et al. 2019 [38]	42 million (20.3)	5.2 million (204.3)	N/A	N/A
Zou et al. 2014 [39]	642,036 (6.17)	611,796 (67.78)	N/A	N/A
Nakashima et al. 2011 [45]	N/A	N/A	141,957 (0)	149,790 (9.3)
Vilar et al. 2011[46]	N/A	N/A	223,339 (2.2 (95% CI 0.7–5.2))	269,900 (14.1 (95% CI 10.0–19.3))
Gonzalez et al. 2016 [36]	N/A	940,404 (34.9 (95% CI 32.8–41.1))	N/A	940,404 (4.2 (95% CI 2.9–5.8))
Scolnik et al. 2014 [47]	12,795 (23 (CI 95% 11.9–40.1))	115,163 (83.2 (CI 95% 63.9–106.4))	12,795 (2.6 (CI 1.2–3.9))	115,163 (8.9 (CI 95% 6.6–11.2))
Nasonov et al. 2014 [48]	183,600 (3.7 (CI 1.2–8.7))	229,900 (23.8 (CI 17.0–32.4))	N/A	N/A
Senna et al. 2004 [49]	1109 (90 (CI 0.0–260))	1929 (110 (CI 0.0–240))	N/A	N/A
Li et al. 2012 [52]	5223 (0)	5333 (60 (95% CI 10, 170))	N/A	N/A
Quintana et al. 2016 [58]	0	90 (95% CI 2–500)	N/A	N/A
Gheita et al. 2021 [57]	365 (1.2)	3296 (11.3)	N/A	N/A

N/A Not available

India, Kenya, Malaysia, Mexico, Nigeria, Pakistan, Turkey, Ukraine, Venezuela, and Zimbabwe. The prevalence and incidence of SLE ranged from 3.2 to 3000 per 100,000 and 0.3 to 8.7 per 100,000 persons, respectively. The highest estimates of incidence and prevalence of SLE were in Brazil [8.7(95% CI 6.3–11.7)/100 000 persons and in Kenya 3000 [95% 1800–5600]/100 000 persons, respectively. The lowest incidences of SLE were reported in Ukraine (0.3 (95% CI 0.0–1.8)/100 000 people, and the lowest prevalence was in India 3.2 (95% CI 0–6.86)/100,000 persons. Compared to high income countries, a lower prevalence of SLE is reported in LMICs. A systematic review on the incidence and prevalence of SLE reported that people in the United States of America (USA) 241/100 000 have much lower prevalence than people in Kenya 3000/100,000 [31]. On the other hand, evidence suggested that the highest incidence of SLE is reported in the USA (23.2/100 000 person-years) compared to Africa [1].


However, the results of the current review indicated that SLE is common in LMICs and the variation is considerably high across these countries. This variation is attributable to a variety of factors including the definition of SLE applied, ethnic and geographic differences in the populations being studied, access to health care, environmental (infections and ultraviolet light) and the methods of case identification [6, 59]. The incidence of SLE in Ukraine and Zimbabwe was the lowest compared to other countries in LMICs, this may be due to methodological differences used to collect the data. For example, the data sources and

the skills used to identify SLE cases in Zimbabwe were inadequate, this is due to the data collected were relied upon hospital admission of one study hospital, and the low life expectancy of patients. On the other hand, the high prevalence estimate of SLE was reported in the Kenya, Nigeria, Colombia and Mexico, this may be because of an unadjusted rate in the population at risk.


Although the ratio varies, the prevalence and incidence estimate of SLE is more common in women than men. This may be due to oestrogen, a stimulant of lymphocytes, where women continue to have the higher oestrogen activity [60]. Moreover, clear differences in women and men immunity may also contribute to variation in response to predisposition of SLE [61, 62]. Most of the included studies in the current review reported a substantial difference of the prevalence and incidence of men and women. One study reported a prevalence rate of females (204) and male (20.3) per 100,000 persons [38]. The Incidence rate comparison between sexes also indicated this phenomenon, with one study contributing to the considerable variations of people with SLE in females compared to males [46].

Some studies that analysed the difference of occurrence of SLE among various ethnic groups in our review reported that black people to have high prevalence and incidence of SLE than white people [36, 46, 49]. It is also important to point out that there are studies that reported low incidence of SLE in black African population [43, 44]. The variation in the epidemiology of SLE is associated not only with genetic


Fig. 4 Incidence and prevalence of SLE stratified by years



a) Annual incidence of SLE, 2005 - 2012 in Tucumán, Argentina



b) Incidence rates of SLE by four-year periods (2003–2006, 2007–2010, 2011–2014) in Turkey.



c) Prevalence of SLE between 2012 and 2016 in Colombia

but also with environmental, sociodemographic, and socio-cultural factors [61].

There are some strengths and limitations to be considered when interpreting the findings of this review. When identifying the relevant studies on prevalence and incidence of SLE, a systematic and rigorous approach was adopted. The adoption of different methodologies such as case identification method and analytical issues within the included studies have made it difficult to assess the epidemiological trend over time. Although an extensive literature search was carried out, we did not search for papers published in languages other than English, this could have influenced the incidence and prevalence estimates of SLE in LMICs. Due to the lack of financial resources and an inadequate health professional workforce, rheumatology services are limited or non-existent in many parts of Southeast Asia and sub-Saharan Africa [62, 63]. These

may have resulted patients to a less likely to be diagnosed with SLE. The clinical and policy implications of this review is related with the female population who are at risk of SLE, it may help in the allocation of healthcare resources as well as priority for research funding. Moreover, the lack of epidemiological studies of SLE in Africa requires attention from researchers, and clinical and policy makers to understand its burden with the hope of improving the health outcomes of people with SLE in LMICs.

Conclusions

Systemic lupus erythematosus is a common condition with considerable variation in prevalence and incidence among the general population in LMICs. The findings also suggested that the incidence and prevalence of SLE is higher

in females compared with males. Furthermore, the trend of prevalence of SLE is increasing with time. The same to other public health problems, it is crucial for policy makers to intervene in the prevention and management of SLE. Furthermore, urgent need of research in terms of estimating its direct and indirect costs and impaired health related quality of life due to the condition is necessary in LMICs settings.

Author contributions FF, TG and CM have contributed equally to this paper. All authors had conceived, designed, analysed the data, and interpreted the results of the work. All co-authors take full responsibility for the accuracy and integrity of all aspects of the work. All authors approved the final version of this manuscript.

Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declarations

Competing interests The authors have no competing interests to declare.

Ethical approval The study is a systematic review. For this study ethical approval was not required. Note: Abstract for this study has already been published previously <https://www.sciencedirect.com/science/article/pii/S109830152101367X>.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W (2017) The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. *Rheumatology* 56(11):1945–1961
2. Fava A, Petri M (2019) Systemic lupus erythematosus: diagnosis and clinical management. *J Autoimmun* 96:1–13
3. Blomberg J, Nived O, Pipkorn R, Bengtsson A, Erlinge D, Sturfelt G (1994) Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus. *Arthritis & Rheum: Off J Am Coll Rheumatol* 37(1):57–66
4. Tsokos GC, Lo MS, Reis PC, Sullivan KE (2016) New insights into the immunopathogenesis of systemic lupus erythematosus. *Nat Rev Rheumatol* 12(12):716–730
5. Generali E, Ceribelli A, Stazi MA, Selmi C (2017) Lessons learned from twins in autoimmune and chronic inflammatory diseases. *J Autoimmun* 83:51–61
6. Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. *Nat Rev Rheumatol* 12(10):605–620
7. Yen EY, Singh RR (2018) Brief report: lupus—an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000–2015. *Arthritis Rheumatol* 70(8):1251–1255
8. Lee YH, Choi SJ, Ji JD, Song GG (2016) Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. *Lupus* 25(7):727–734
9. Symmons DPM (1995) Occasional series: lupus around the world frequency of lupus in people of African origin. *Lupus* 4(3):176–178
10. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. *Semin Arthritis Rheum* 39(4):257–268
11. Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. *Lupus* 15(5):308–318
12. Ferucci ED, Johnston JM, Gaddy JR, Sumner L, Posever JO, Choromanski TL, Helmick CG (2014) Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007–2009. *Arthritis Rheumatol* 66(9):2494–2502
13. Krishnan E, Hubert HB (2006) Ethnicity and mortality from systemic lupus erythematosus in the US. *Ann Rheum Dis* 65(11):1500–1505
14. Petri M, Robinson C (1997) Oral contraceptives and systemic lupus erythematosus. *Arthritis Rheum* 40(5):797–803
15. González LA, Toloza SMA, McGwin G Jr, Alarcón GS (2013) Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. *Lupus* 22(12):1214–1224
16. Lerang K, Gilboe I, Garen T, Thelle DS, Gran JT (2012) High incidence and prevalence of systemic lupus erythematosus in Norway. *Lupus* 21(12):1362–1369
17. Barber MR, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, Ramsey-Goldman R (2021) Publisher correction: global epidemiology of systemic lupus erythematosus. *Nat Rev Rheumatol* 17(10):642
18. Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N (2012) Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. *Arthritis Care Res* 64(2):159–168
19. Bertsias G, Karampli E, Sidiropoulos P, Gergianaki I, Drosos A, Sakkas L, Boumpas D (2016) Clinical and financial burden of active lupus in Greece: a nationwide study. *Lupus* 25(12):1385–1394
20. Campbell R Jr, Cooper GS, Gilkeson GS (2008) Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. *Arthritis Care Res* 59(4):458–464
21. Essouma M, Nkeck JR, Endomba FT, Bigna JJ, Ralandison S (2020) Epidemiology of rheumatoid arthritis in sub-Saharan Africa: a systematic review and meta-analysis protocol. *Syst Rev* 9(1):1–4
22. Li S, Gong T, Peng Y, Nieman KM, Gilbertson DT (2020) Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009–2016 US Medicare population. *Lupus* 29(1):15–26
23. McMurray RW, May W (2003) Sex hormones and systemic lupus erythematosus: review and meta-analysis. *Arthritis Rheum: Off J Am Coll Rheumatol* 48(8):2100–2110
24. Dave M, Rankin J, Pearce M, Foster HE (2020) Global prevalence estimates of three chronic musculoskeletal conditions:

- club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. *Pediatr Rheumatol* 18(1):1–7
25. Lewandowski LB, Schanberg LE, Thielman N, Phuti A, Kalla AA, Okpechi I, Scott C (2017) Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. *Lupus* 26(2):186–194
 26. Aggarwal A, Phatak S, Srivastava P, Lawrence A, Agarwal V, Misra R (2018) Outcomes in juvenile onset lupus: single center cohort from a developing country. *Lupus* 27(11):1867–1875
 27. Fessel WJ (1974) Systemic lupus erythematosus in the community: incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. *Arch Intern Med* 134(6):1027–1035
 28. Tikly M, Navarra SV (2008) Lupus in the developing world—is it any different? *Best Pract Res Clin Rheumatol* 22(4):643–655
 29. Mody GM (2019) Rheumatology in Africa—challenges and opportunities. *Arthritis Res Ther* 219(1):1–3
 30. Magro R, Borg AA (2018) Characterisation of patients with systemic lupus erythematosus in Malta: a population based cohort cross-sectional study. *BioMed Res Int* 2018:1–7
 31. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 151(4):264–269
 32. Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum: Off J Am Coll Rheumatol* 25(11):1271–1277
 33. Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 40(9):1725–1725
 34. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Buchbinder R (2012) Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol* 65(9):934–939
 35. Borenstein M, Rothstein H, Cohen J (1999) Comprehensive meta-analysis: a computer program for research synthesis
 36. Gonzalez Lucero L, Barbaglia AL, Bellomio VI, Bertolaccini MC, Machado Escobar MA, Sueldo HR, Lucero E (2020) Prevalence and incidence of systemic lupus erythematosus in Tucumán. *Argent Lupus* 29(13):1815–1820
 37. Pamuk ON, Balci MA, Donmez S, Tsokos GC (2016) The incidence and prevalence of systemic lupus erythematosus in Thrace, 2003–2014: a 12-year epidemiological study. *Lupus* 25(1):102–109
 38. Fernández-Ávila DG, Bernal-Macías S, Rincón-Riaño DN, Gutiérrez Dávila JM, Rosselli D (2019) Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012–2016. *Lupus* 28(10):1273–1278
 39. Zou YF, Feng CC, Zhu JM, Tao JH, Chen GM, Ye QL, Ye DQ (2014) Prevalence of systemic lupus erythematosus and risk factors in rural areas of Anhui Province. *Rheumatol Int* 34(3):347–356
 40. Ekwom PE (2013) Systemic lupus erythematosus (SLE) at the Kenyatta national hospital. *Clin Rheumatol* 32(8):1215–1217
 41. Gbané-Koné M, Ouattara B, Djaha KJM, Megne E, Ngandeu AN, Coulibaly AK, Kouakou MNZ (2015) Autoantibodies in systemic lupus erythematosus, on Black African subject, in Abidjan. *Open J Rheumatol Autoimmune Dis* 5(02):28
 42. Wang F, Wang CL, Tan CT, Manivasagar M (1997) Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups. *Lupus* 6(3):248–253
 43. Farooqi A, Gibson T (1998) Prevalence of the major rheumatic disorders in the adult population of north Pakistan. *Br J Rheumatol* 37(5):491–495
 44. Taylor HG, Stein CM (1986) Systemic lupus erythematosus in Zimbabwe. *Ann Rheum Dis* 45(8):645–648
 45. Nakashima CAK, Galhardo AP, Silva JFMD, Fiorenzano GR, Santos ABDSD, Leite MFS, Menolli RA (2011) Incidence and clinical-laboratory aspects of systemic lupus erythematosus in a Southern Brazilian city. *Rev Bras Reumatol* 51:235–239
 46. Vilar MP, Sato EI (2002) Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). *Lupus* 11(8):528–532
 47. Scolnik M, Marin J, Valeiras SM, Marchese MF, Talani AS, Avellaneda NL, Soriano ER (2014) Incidence and prevalence of lupus in Buenos Aires, Argentina: a 11-year health management organisation-based study. *Lupus Sci Med* 1(1):e000021
 48. Nasonov E, Soloviev S, Davidson JE, Lila A, Ivanova R, Togizbayev G, Pereira MHS (2014) The prevalence and incidence of systemic lupus erythematosus (SLE) in selected cities from three commonwealth of independent states countries (the Russian Federation, Ukraine and Kazakhstan). *Lupus* 23(2):213–219
 49. Senna ER, De Barros ALP, Silva EO, Costa IF, Pereira LVB, Ciconelli RM, Ferraz MB (2004) Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. *J Rheumatol* 31(3):594–597
 50. Granados Y, Cedeño L, Rosillo C, Berbin S, Azocar M, Molina ME, Peláez-Ballestas I (2015) Prevalence of musculoskeletal disorders and rheumatic diseases in an urban community in Monagas State, Venezuela: a COPCORD study. *Clin Rheumatol* 34(5):871–877
 51. Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, Cardiel MH (2011) Epidemiology of the rheumatic diseases in Mexico. a study of 5 regions based on the COPCORD methodology. *J Rheumatol Suppl* 86:3–8
 52. Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, Li ZG (2012) Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. *Rheumatology* 51(4):721–729
 53. Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A (1993) Prevalence of systemic lupus erythematosus in India. *Lupus* 2(2):115–118
 54. Malemba JJ, Mbuyi-Muamba JM (2008) Clinical and epidemiological features of rheumatic diseases in patients attending the university hospital in Kinshasa. *Clin Rheumatol* 27(1):47–54
 55. Guevara-Pacheco S, Feicán-Alvarado A, Sanín LH, Vintimilla-Ugalde J, Vintimilla-Moscoso F, Delgado-Pauta J, Peláez-Ballestas I (2016) Prevalence of musculoskeletal disorders and rheumatic diseases in Cuenca, Ecuador: a WHO-ILAR COPCORD study. *Rheumatol Int* 36(9):1195–1204
 56. Reyes-Llerena GA, Guibert-Toledano M, Penedo-Coello A, Pérez-Rodríguez A, Baez-Dueñas RM, Charnicharo-Vidal R, Cardiel MH (2009) Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. *JCR: J Clin Rheumatol* 15(2):51–55
 57. Gheita TA, Noor RA, Abualfadel E, Abousehly OS, El-Gazzar II, El Shereef RR, Raafat HA (2021) Adult systemic lupus erythematosus in Egypt: the nation-wide spectrum of 3661 patients and world-wide standpoint. *Lupus* 30(9):1526–1535
 58. Quintana R, Silvestre AM, Goñi M, García V, Mathern N, Jorfen M, Pons-Estel BA (2016) Prevalence of musculoskeletal disorders and rheumatic diseases in the indigenous Qom population of Rosario. *Argent Clin Rheumatol* 35(1):5–14
 59. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, Costenbader KH (2013) Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. *Arthritis Rheum* 65(3):753–763

60. Tiffin N, Adeyemo A, Okpechi I (2013) A diverse array of genetic factors contribute to the pathogenesis of systemic lupus erythematosus. *Orphanet J Rare Dis* 8(1):1–8
61. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. *Autoimmun Rev* 9(5):A277–A287
62. Pineles D, Valente A, Warren B, Peterson MGE, Lehman TJA, Moorthy LN (2011) Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. *Lupus* 20(11):1187–1192
63. Webb K, Peckham H, Radziszewska A, Menon M, Oliveri P, Simpson F, Ioannou Y (2019) Sex and pubertal differences in

the type 1 interferon pathway associate with both X chromosome number and serum sex hormone concentration. *Front Immunol* 9:3167

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.